Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-12-02 pm EST
178.88 USD   +0.08%
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
12/01Global markets live: General Electric, Tesla, Apple, Salesforce, Boeing...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

J&J's talc Texas two-step called out by victims

09/21/2022 | 01:31am EST

PEOPLE suing Johnson & Johnson (J&J) over the company's talc products urged an appeals court on Monday to revive their claims, saying the profitable company should not be allowed to use a bankrupt subsidiary to block lawsuits alleging the products cause cancer.

They asked a panel of the Philadelphia-based third US Circuit Court of Appeals to dismiss the bankruptcy of J&J's subsidiary LTL Management, saying that LTL is a "concocted" corporation set up solely to stop them from getting their day in court.

J&J, which maintains its talc products are safe, spun off LTL in October, assigned its talc liabilities to it and placed the newly created subsidiary into bankruptcy days later.

That restructuring strategy, known as the "Texas two-step", paused about 38,000 lawsuits J&J was facing alleging its baby powder and other talc-based products contain asbestos and caused mesothelioma and ovarian cancer.

Critics, including lawmakers and legal experts, say J&J's bankruptcy maneuver could provide a blueprint for other big companies to avoid juries in mass tort lawsuits.

Circuit Judge Julio Fuentes at Monday's arguments asked the cancer victims' attorney Jeffrey Lamken whether the bankruptcy court could provide a more efficient resolution of the claims than trying cases one at a time in other courts. Lamken said the court should not make a general ruling about whether bankruptcy is "better" because its protections should be reserved for companies that are in financial distress.

David Frederick, representing a separate group of cancer plaintiffs, said the bankruptcy allows LTL to pay "less money, more slowly". But J&J countered bankruptcy court allows all talc lawsuits to be settled together, which it says is the fastest and fairest way.

J&J has set aside $2bn (£1.7bn) to settle talc claims, which LTL executives describe as a starting point rather than a "cap". Before the bankruptcy filing, J&J faced costs from $3.5bn in verdicts and settlements.

Reuters

(c) 2022 City A.M., source Newspaper

All news about JOHNSON & JOHNSON
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
12/01Global markets live: General Electric, Tesla, Apple, Salesforce, Boe..
MS
12/01There are two ways to look at Powell's speech
MS
12/01Morgan Stanley Adjusts Price Target on Johnson & Johnson to $178 From $170, Maintains E..
MT
12/01First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results ..
AQ
12/01Johnson & Johnson : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
11/30J&J CEO Joaquin Duato to take additional role of Chairman
RE
11/30Johnson & Johnson Chief Executive Joaquin Duato to Also Assume Chairman Role
MT
11/30Johnson & Johnson CEO Joaquin Duato to Become Chairman of the Board
DJ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 035 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 22,0x
Yield 2022 2,43%
Capitalization 468 B 468 B -
EV / Sales 2022 4,81x
EV / Sales 2023 4,59x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 178,88 $
Average target price 181,90 $
Spread / Average Target 1,69%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY34.07%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774
MERCK & CO., INC.43.58%278 995